{
  "first_published_at": "2011-04-04", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON111770", 
  "title": "Vivaglobin solution for subcutaneous injection: rare risk of thromboembolic events", 
  "tags": "{\"parsed_therapeutic\": [\"immunology-vaccination\", \"cancer\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Immunology and vaccination\", \"Cancer\"]}", 
  "_document_number": 156, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "immunology-vaccination", 
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Vivaglobin solution for subcutaneous injection: rare risk of thromboembolic events</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: April 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Prescribers should be vigilant for signs of arterial or venous thromboembolism in patients who are given Vivaglobin. Where possible, use alternative appropriate therapy for patients with risk factors for thromboembolism.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Vivaglobin 160 mg/mL (human normal immunoglobin solution for subcutaneous injection) is licensed as replacement therapy for adults and children with primary immunodeficiency syndromes, myeloma, or chronic lymphatic leukaemia.</p><p>There have been rare and unexpected reports from outside the UK of thromboembolic events such as stroke, myocardial infarction, deep vein thrombosis and pulmonary embolism in association with Vivaglobin use.</p><p>Investigations revealed pro-coagulant activity of some batches. The affected batches are no longer being distributed by the manufacturer (although some may still be in use), and only batches with low pro-coagulant activity will be distributed in future. A supply shortage is not envisaged and alternative treatments are available.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><br>\r\n\t\t\t\t<font class=\"h3\">Advice for healthcare professionals:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Where possible, use an appropriate alternative therapy for patients at increased risk of thrombosis.</li>\r\n\t\t\t\t<li>Vivaglobin is not indicated for intravenous use. Do not infuse Vivaglobin intravenously and make sure that no vessel is damaged during subcutaneous injection.</li>\r\n\t\t\t\t<li>Be extra vigilant for signs of a thromboembolic event in patients who receive Vivaglobin, particularly if they have pre-existing risk factors.</li>\r\n\t\t\t\t<li>Patients should be advised to seek immediate medical attention if first symptoms of a thromboembolic event occur, such as shortness of breath, pain and swelling of a limb, focal neurological deficits, chest pain, or other manifestations.</li>\r\n\t\t\t\t<li>Report any suspected adverse reactions with Vivaglobin through the Yellow Card Scheme at <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a></li>\r\n\t\t\t</ul></div><p><br><font class=\"h3\">Further information:</font></p><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111795\" target=\"_blank\">See letter for healthcare professionals sent March 2011</a></p><p>BNF section 14.5.1 <a href=\"http://bnf.org/bnf/bnf/61/129302.htm?q=Vivaglobin&t=search&ss=text&p=1\" target=\"_blank\">Normal immunoglobin for subcutaneous use</a>&nbsp;(external link)</p><p><br><em>Article citation: Drug Safety Update April 2011; vol 4 issue 9: S1<br></em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Vivaglobin 160 mg/mL (human normal immunoglobin solution for subcutaneous injection) is licensed as replacement therapy for adults and children with primary immunodeficiency syndromes, myeloma, or chronic lymphatic leukaemia.</p><p>There have been rare and unexpected reports from outside the UK of thromboembolic events such as stroke, myocardial infarction, deep vein thrombosis and pulmonary embolism in association with Vivaglobin use.</p><p>Investigations revealed pro-coagulant activity of some batches. The affected batches are no longer being distributed by the manufacturer (although some may still be in use), and only batches with low pro-coagulant activity will be distributed in future. A supply shortage is not envisaged and alternative treatments are available.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><br>\r\n\t\t\t\t<font class=\"h3\">Advice for healthcare professionals:</font></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Where possible, use an appropriate alternative therapy for patients at increased risk of thrombosis.</li>\r\n\t\t\t\t<li>Vivaglobin is not indicated for intravenous use. Do not infuse Vivaglobin intravenously and make sure that no vessel is damaged during subcutaneous injection.</li>\r\n\t\t\t\t<li>Be extra vigilant for signs of a thromboembolic event in patients who receive Vivaglobin, particularly if they have pre-existing risk factors.</li>\r\n\t\t\t\t<li>Patients should be advised to seek immediate medical attention if first symptoms of a thromboembolic event occur, such as shortness of breath, pain and swelling of a limb, focal neurological deficits, chest pain, or other manifestations.</li>\r\n\t\t\t\t<li>Report any suspected adverse reactions with Vivaglobin through the Yellow Card Scheme at <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a></li>\r\n\t\t\t</ul></div><p><br><font class=\"h3\">Further information:</font></p><p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111795\" target=\"_blank\">See letter for healthcare professionals sent March 2011</a></p><p>BNF section 14.5.1 <a href=\"http://bnf.org/bnf/bnf/61/129302.htm?q=Vivaglobin&amp;t=search&amp;ss=text&amp;p=1\" target=\"_blank\">Normal immunoglobin for subcutaneous use</a>&#160;(external link)</p><p><br><em>Article citation: Drug Safety Update April 2011; vol 4 issue 9: S1<br></em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-04-01", 
  "date_last_modified": "2011-04-01", 
  "_assets": [], 
  "_item_id": 156, 
  "summary": "", 
  "body": "Article date: April 2011\n\nVivaglobin 160 mg/mL (human normal immunoglobin solution for subcutaneous injection) is licensed as replacement therapy for adults and children with primary immunodeficiency syndromes, myeloma, or chronic lymphatic leukaemia.\n\nThere have been rare and unexpected reports from outside the UK of thromboembolic events such as stroke, myocardial infarction, deep vein thrombosis and pulmonary embolism in association with Vivaglobin use.\n\nInvestigations revealed pro-coagulant activity of some batches. The affected batches are no longer being distributed by the manufacturer (although some may still be in use), and only batches with low pro-coagulant activity will be distributed in future. A supply shortage is not envisaged and alternative treatments are available.\n\n  \nAdvice for healthcare professionals:  \n  \n  * Where possible, use an appropriate alternative therapy for patients at increased risk of thrombosis.  \n  * Vivaglobin is not indicated for intravenous use. Do not infuse Vivaglobin intravenously and make sure that no vessel is damaged during subcutaneous injection.  \n  * Be extra vigilant for signs of a thromboembolic event in patients who receive Vivaglobin, particularly if they have pre-existing risk factors.  \n  * Patients should be advised to seek immediate medical attention if first symptoms of a thromboembolic event occur, such as shortness of breath, pain and swelling of a limb, focal neurological deficits, chest pain, or other manifestations.  \n  * Report any suspected adverse reactions with Vivaglobin through the Yellow Card Scheme at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk/)  \n  \n  \nFurther information:\n\n[See letter for healthcare professionals sent March 2011](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON111795)\n\nBNF section 14.5.1 [Normal immunoglobin for subcutaneous use](http://bnf.org/bnf/bnf/61/129302.htm?q=Vivaglobin&t=search&ss=text&p=1)Â (external link)\n\n  \nArticle citation: Drug Safety Update April 2011; vol 4 issue 9: S1  \n\n"
}